References
- Kane S. NOAC, DOAC, or TSOAC: What should we call novel oral anticoagulants? Pharmacy Times 2016 Sept. 19. Retrieved from: https://www.pharmacytimes.com/contributor/sean-kane-pharmd/2016/09/noac-doac-or-tsoac-what-should-we-call-novel-oral-anticoagulants
- Wells G, Coyle D, Cameron C, Steiner S, Coyle K, Kelly S, Tang A, Healey J, Hsieh S, Van Berkom J. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, Apr 9, 2012. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK169793
- Jonas DE, Bryant Shilliday B, Laundon WR, et al. Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making. 2010;30:206–216.
- Aziz F, Corder M, Wolffe J, et al. Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg. 2011;54:1404–1407.
- Sullivan PW, Arant TW, Ellis SL, et al. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. PharmacoEconomics. 2006;24:1021–1033.
- Bauersachs R. Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups. Eur J Int Med. 2014;25:600–606.
- Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52:69–82.
- Singh SM, Wijeysundera HC. Cost-effectiveness of novel oral anticoagulants for stroke prevention in non-valvular atrial fibrillation. Curr Cardiol Rep. 2015; 17:61.
- Amin A, Stokes M, Makenbaeva D, et al. Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. J Med Econ. 2014;17:771–781.
- Kaplan RS, Porter ME. How to solve the cost crisis in health care. Harvard Business Review. Sept. 2011. Retrieved from: https://ie.technion.ac.il/∼serveng/course2004/Lectures/Kaplan_Porter_2011-9_How-to-Solve-the-Cost-Crisis-in-Health-Care_HBR.pdf
- Kaplan RS. Improving value with TDABC. Health Care Financial Manage. 2014;68:76–83.
- Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.